Digital Inhaler Dosage The Rising Prevalence Of Respiratory Diseases
The increase in the frequency of long-term respiratory conditions, such as respiratory allergies, asthma, and chronic obstructive pulmonary disease (COPD), among others, and the
The Global digital dose inhaler market is estimated to be valued at US$ 64.33 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Digital Dose Inhaler Market Size are 3M, AstraZeneca, GLENMARK PHARMACEUTICALS LTD., Novartis AG, Sensirion AG, Propeller Health, OPKO Health, Inc., Teva Pharmaceutical Industries Ltd., BEXIMCO Pharmaceuticals, GSK plc., Mundipharma International, Honeywell International Inc., Veranex, Cognita Labs. These players are focusing on developing smart connected inhalers with advanced sensors and mobile applications for remote monitoring.
The growing prevalence of respiratory diseases like asthma and COPD worldwide is expected to drive the demand for digital dose inhalers. Easy to use features and feedback on dose intake can help patients better manage their condition and ensure medication adherence.
The global digital dose inhaler market is anticipated to witness significant expansion as key players focus on commercializing their products across different geographies. Partnerships with local pharma companies help achieve wider market penetration. Regulatory approvals in emerging nations will further accelerate the adoption of digital inhalers.
Get more insights on Digital Dose Inhaler Market
Also read related article on Digital Dose Inhaler Market
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian